HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug Delivery Co., Ltd through its subsidiary, Sichuan Xiandong Pharmaceutical Co., Ltd. This alliance is aimed at the research and development (R&D) and manufacturing of nucleic acid drugs, marking a significant step forward in the field of genetic medicine.
The collaboration will see the two firms jointly develop an innovative nucleic acid drug R&D technology platform, integrating expertise in raw materials and formulations to enhance drug efficacy and delivery. The agreement encompasses a comprehensive collaboration in the realms of formulation technology development and sample production, establishing a synergy that combines “raw material innovation with formulation innovation.”
While the financial specifics of the partnership were not disclosed, the move signals a commitment by both companies to push the boundaries of nucleic acid drug development, potentially leading to breakthroughs in treating a variety of diseases.- Flcube.com
